FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134462904> ?p ?o ?g. }

• W3134462904 endingPage "468" @default.
• W3134462904 startingPage "458" @default.
• W3134462904 abstract "To assess from a US payer perspective the cost-effectiveness of the chimeric antigen receptor T (CAR T)-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL) following ≥2 systemic therapy lines.A three-state (i.e. pre-progression, post-progression, and death) partitioned survival model was used to estimate the quality-adjusted life-years (QALYs) and costs for patients on each treatment over a lifetime horizon. Progression-free survival (PFS) and overall survival (OS) were based on a matching-adjusted indirect treatment comparison (MAIC) that accounted for differences in trial population baseline characteristics. Mixture cure models (MCMs) were used to account for long-term survivors. Costs included drug acquisition and administration for the CAR T-cell therapies and conditioning chemotherapy, apheresis, CAR T-specific monitoring, transplant, hospitalization, adverse events, routine care, and terminal care. Health state utilities were derived from trial and published data. Sensitivity analyses included probabilistic sensitivity analyses (PSAs) and an analysis of extremes that assessed the results across a vast array of combinations of parametric OS and PFS curves across the two therapies.Compared to tisa-cel, axi-cel resulted in 2.31 QALYs gained and a cost reduction of $1,407 in the base case. In the PSA, the cost per QALY gained was ≤$31,500 in 95% of the 1,000 simulations. In the analysis of extremes, the cost per QALY gained was ≤$7,500 in 99% of the 1,296 combinations of MCMs and ≤$40,000 in 95% of the 1,296 combinations of standard models.In absence of head-to-head comparative data, we relied on a MAIC, which cannot account for all possible confounders. Moreover, some outcomes (i.e. transplantations, hospitalizations, adverse events (AEs)) were not adjusted in the MAIC.In this simulation, axi-cel was a superior treatment option as it is predicted to achieve better outcomes at lower or minimal incremental costs versus tisa-cel." @default.
• W3134462904 created "2021-03-15" @default.
• W3134462904 creator A5021394406 @default.
• W3134462904 creator A5027316831 @default.
• W3134462904 creator A5030572351 @default.
• W3134462904 creator A5035175326 @default.
• W3134462904 creator A5084342658 @default.
• W3134462904 creator A5087184017 @default.
• W3134462904 date "2021-01-01" @default.
• W3134462904 modified "2023-10-16" @default.
• W3134462904 title "Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States" @default.
• W3134462904 cites W1972744813 @default.
• W3134462904 cites W1982967337 @default.
• W3134462904 cites W2062126843 @default.
• W3134462904 cites W2092901728 @default.
• W3134462904 cites W2098914901 @default.
• W3134462904 cites W2130185170 @default.
• W3134462904 cites W2133345449 @default.
• W3134462904 cites W2134365788 @default.
• W3134462904 cites W2150587745 @default.
• W3134462904 cites W2150712216 @default.
• W3134462904 cites W2172003817 @default.
• W3134462904 cites W2174429140 @default.
• W3134462904 cites W2305142474 @default.
• W3134462904 cites W2382078359 @default.
• W3134462904 cites W2470555690 @default.
• W3134462904 cites W2519603001 @default.
• W3134462904 cites W2559431510 @default.
• W3134462904 cites W2744261860 @default.
• W3134462904 cites W2765198305 @default.
• W3134462904 cites W2773804840 @default.
• W3134462904 cites W2889646458 @default.
• W3134462904 cites W2893050608 @default.
• W3134462904 cites W2903062212 @default.
• W3134462904 cites W2917035693 @default.
• W3134462904 cites W2920602503 @default.
• W3134462904 cites W2924528896 @default.
• W3134462904 cites W2924628923 @default.
• W3134462904 cites W2948047060 @default.
• W3134462904 cites W2949814266 @default.
• W3134462904 cites W2952887953 @default.
• W3134462904 cites W2985681155 @default.
• W3134462904 cites W3034030759 @default.
• W3134462904 cites W3035443948 @default.
• W3134462904 cites W3044545425 @default.
• W3134462904 cites W3087313208 @default.
• W3134462904 cites W3142450396 @default.
• W3134462904 cites W4236710883 @default.
• W3134462904 cites W4249178543 @default.
• W3134462904 doi "https://doi.org/10.1080/13696998.2021.1901721" @default.
• W3134462904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33691581" @default.
• W3134462904 hasPublicationYear "2021" @default.
• W3134462904 type Work @default.
• W3134462904 sameAs 3134462904 @default.
• W3134462904 citedByCount "19" @default.
• W3134462904 countsByYear W31344629042021 @default.
• W3134462904 countsByYear W31344629042022 @default.
• W3134462904 countsByYear W31344629042023 @default.
• W3134462904 crossrefType "journal-article" @default.
• W3134462904 hasAuthorship W3134462904A5021394406 @default.
• W3134462904 hasAuthorship W3134462904A5027316831 @default.
• W3134462904 hasAuthorship W3134462904A5030572351 @default.
• W3134462904 hasAuthorship W3134462904A5035175326 @default.
• W3134462904 hasAuthorship W3134462904A5084342658 @default.
• W3134462904 hasAuthorship W3134462904A5087184017 @default.
• W3134462904 hasBestOaLocation W31344629041 @default.
• W3134462904 hasConcept C112930515 @default.
• W3134462904 hasConcept C121608353 @default.
• W3134462904 hasConcept C126322002 @default.
• W3134462904 hasConcept C143998085 @default.
• W3134462904 hasConcept C2777701055 @default.
• W3134462904 hasConcept C2908647359 @default.
• W3134462904 hasConcept C3019080777 @default.
• W3134462904 hasConcept C3875195 @default.
• W3134462904 hasConcept C64332521 @default.
• W3134462904 hasConcept C71924100 @default.
• W3134462904 hasConcept C99454951 @default.
• W3134462904 hasConceptScore W3134462904C112930515 @default.
• W3134462904 hasConceptScore W3134462904C121608353 @default.
• W3134462904 hasConceptScore W3134462904C126322002 @default.
• W3134462904 hasConceptScore W3134462904C143998085 @default.
• W3134462904 hasConceptScore W3134462904C2777701055 @default.
• W3134462904 hasConceptScore W3134462904C2908647359 @default.
• W3134462904 hasConceptScore W3134462904C3019080777 @default.
• W3134462904 hasConceptScore W3134462904C3875195 @default.
• W3134462904 hasConceptScore W3134462904C64332521 @default.
• W3134462904 hasConceptScore W3134462904C71924100 @default.
• W3134462904 hasConceptScore W3134462904C99454951 @default.
• W3134462904 hasIssue "1" @default.
• W3134462904 hasLocation W31344629041 @default.
• W3134462904 hasLocation W31344629042 @default.
• W3134462904 hasOpenAccess W3134462904 @default.
• W3134462904 hasPrimaryLocation W31344629041 @default.
• W3134462904 hasRelatedWork W2022229528 @default.
• W3134462904 hasRelatedWork W2092414428 @default.
• W3134462904 hasRelatedWork W2106485849 @default.
• W3134462904 hasRelatedWork W2346894020 @default.
• W3134462904 hasRelatedWork W2797250355 @default.

• next